The MARIPOSA study suggests there may be a new preferred first line regimen (amivantamab + lazertinib) for metastatic EGFR-mutated NSCLC, as this regimen improved PFS compared to osimertinib.Από τον John Bossaer

An experimental regimen for DLBCL piques my interest.VenetoclaxibrutinibPrednisoneObinutuzumabRevlimid (lenalidomide)Link: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2401532Από τον John Bossaer

A new drug is approved for MDS. While some will likely benefit from this new agent, the more enticing news is that inhibiting telomerase may be an attractive target for many malignancies.Από τον John Bossaer

Lots and lots of updates from the past weekend's ASCO annual meeting.1. ADRIATIC (consolidation durvalumab in limited stage SCLC)2. NADINA (neoadjuvant Nivo/Ipi in stage III melanoma)3. *NICHE-2 (neoadjuvant Nivo/Ipi in dMMR colon cancer)4. CheckMate 8HW (Nivo/Ipi in dMMR metastatic colon cancer)5. TRANSMET (liver transplantation in colon cancer wi…

ASCO & ONS (along with pharmacist representation) released updated safety standards for preparing, administering, and monitoring chemotherapy. Look for a calendar invitation to review your site's policies soon.Link: https://doi.org/10.1200/OP.24.00216Από τον John Bossaer

A new drug for small-cell lung cancer, a bispecific, targeting DLL3 on small-cell lung cancer and CD3 on T-cells is FDA approved. But, infigratinib's FDA approval for cholangiocarcinoma is withdrawn.Από τον John Bossaer

QT interval prolongation is a common hurdle to taking care of cancer patients. We dive into what QT interval prolongation is, why it matters, risk factors, and prevention/management strategies.Από τον John Bossaer

The non-Award Winning series of Landmarks in OncoPharm returns to discuss a Next Big Thing in NHL that wasn't any better than plain old CHOP.From April 1993, it's Pro-MACE-CytaBOMLink: https://www.nejm.org/doi/full/10.1056/NEJM199304083281404Από τον John Bossaer

Tisotumab vedotin garners a regular FDA approval for metastatic cervical cancer with OS benefit data.A lingering question that demands a focused RCT: What is the optimal dose of methotrexate in primary CNS lymphoma? I'm glad I'm not the only one with this question: https://doi.org/10.1177/10781552231176754What, some BRAF mutations in colorectal can…

Lots of recent updates to cover this week...1. Adjuvant pembrolizumab of RCC demonstrates OS improvement in NEJM publication (DOI: 10.1056/NEJMoa2312695)2. Yet adjuvant nivolumab did not demonstrate OS improvement in the adjuvant setting. There may be a few reasons for this (https://doi.org/10.1200/JCO.2024.42.4_suppl.LBA358)3. A cytokine-fusion pr…

Arguably, the most anticipated release of 4/19/24Από τον John Bossaer

What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma.Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors.Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this we…

Tumor Lysis Syndrome (TLS) is a foundational topic for all oncology clinicians. We discuss the what, the why, prevention, and treatment.Από τον John Bossaer

Discussing four papers that caught our eyes from the last few weeks:Pazopanib vs. placebo following metastatectomy. Always concerning when placebo has an OS advantage.ECOG-ACRIN E2810: https://doi.org/10.1200/JCO.23.01544Gemcitabine vs. Gem + Paclitaxel (Taxol) in pancreatic cancer patients after FOLFIRINOX: https://doi.org/10.1200/JCO.23.00795An R…

Two recent publications suggest more people may be choosing non-colonoscopy screening practices in the future. One is a new stool DNA test, while the other is a blood test.How do they compare to the gold standard of colonoscopy?Cell-free DNA blood test: DOI: 10.1056/NEJMoa2304714Next generation stool DNA test: DOI: 10.1056/NEJMoa2310336…

EV-302 is finally published, and you have to squint to find any major critiques. Enfortumab bedouin + pembrolizumab fully arrives as a standard 1st-line regimen of advanced urothelial cancer.Also, nivolumab gets a 1st-line FDA approval for urothelial carcinoma in conjunction with cisplatin + gemcitabine based on CHECKMATE-901.…

Two nice studies have been recently published in the supportive care realm.SPARED asks if we can omit dexamethasone on days 2-4 following cisplatin-based chemotherapy.D-TORCH asks if topical diclofenac can prevent capecitabine-induced hand-foot syndrome.SPARED: https://doi.org/10.1038/s41416-023-02493-7 D-TORCH: https://doi.org/10.1200/JCO.23.01730…

An exciting new cellular therapy, lifileucel, is approved for metastatic melanoma. The FLAURA2 trial of osimertinib + chemotherapy has led to an FDA approval, but questions remain about a possible new standard of care. And a few minor updates on tepotinib.Από τον John Bossaer

New updates on metastatic pancreatic cancer (NAPOLI-3), upper tract urothelial cancer (POUT), and the drug-drug interaction between ivosidenib and azole antifungals.NAPOLI 3: https://doi.org/10.1016/S0140-6736(23)01366-1POUT (final OS): https://doi.org/10.1200/JCO.23.01659Ivosidenib Azole Antifungal DDIs: https://doi.org/10.1002/cncr.35251…

You know about small cell lung cancer, but let's talk about small cell carcinoma of the prostate.Από τον John Bossaer

In oncology we are always asking questions about which treatment option is best. And that focus on the next best treatment may prevent us from rethinking some fundamentals of current practice. Three recent studies illustrate this and made me ask:Do we need a Port or PICC for every testicular cancer patient?Study: https://doi.org/10.1200/OP.23.00580…

...on FDA approvals for belzutifan for RCC, pembrolizumab + cisplatin/RT for cervical cancer, erdafitinib (FGFR3 alterations only) for bladder cancer.Plus, early morning ICIs (https://doi.org/10.1016/j.ejca.2024.113571)&FLAG-Ida-GO in AML from NCRI AML 19 (https://doi.org/10.1200/JCO.23.00943)Από τον John Bossaer

Special guest Ryan Beechinor joins the pod to discuss his recent paper on the obstacles in the development of generic lenalidomide. It's a fantastic read, and this episode will be a fantastic listen!Link: https://doi.org/10.1016/j.jcpo.2023.100446Από τον John Bossaer

Foundations of OncoPharm episode on lenalidomide (Revlimid) and its MOA, use, dosing, & toxicity.Από τον John Bossaer

A Holiday Tradition returns as we review 14 new OncoPharm drugs approved this past year and ask Keep, Re-Gift, or Return.Από τον John Bossaer

Small bites of updates coming out of ASH's 2023 annual meeting on CLL, multiple myeloma, and lymphoma.Από τον John Bossaer

Our Landmarks of OncoPharm series returns to talk about 2008's VISTA study, which ushered bortezomib into the front line setting, albeit with a now outdated alkylating agent-based backbone.VISTA (VMP vs. MP): https://www.nejm.org/doi/full/10.1056/nejmoa0801479Από τον John Bossaer

The recent approval of nirogacestat, the first gamma secretase inhibitor on the market, provides a great opportunity to discuss desmoid tumors and Notch signaling.Review article: https://doi.org/10.1002/onco.13627Also, a new T-cell malignancy warning for most CAR-T products. And, is belantamab mafodotin coming back based on the DREAMM-7 results?…

FDA has approved two new kinase inhibitors: one for ROS1 (+) NSCLC and one for PIK3CA/AKT/PTEN altered breast cancer.Από τον John Bossaer

This week's Pod dives into a new VEGF-R inhibitor, fruquintinib. We also ask if FLAURA2, osimertinib + chemotherapy in combination, will become a new standard of care in EGFR-mutated metastatic NSCLC.Από τον John Bossaer

Aggressive hematologic malignancy publications can be challenging to interpret and translate to clinical practice.We look at two recent studies to illustrate this point. Elderly AML: 10-day decitabine vs. 7 + 3 (https://doi.org/10.1016/S2352-3026(23)00273-9)Burkitt Lymphoma: R-CODXO-M/R-IVAC vs. DA-R-EPOCH (https://doi.org/10.1016/S2352-3026(23)002…

Out Landmarks of OncoPharm series returns to chronicle how treatment of stage III NSCLC has changed over time with an overview of three studies.1. Dillman (1990) NEJM (sequential chemo --> RT): https://doi.org/10.1056/nejm1990100432314032. Albain (1995) JCO (concurrent cisplatin/etoposide + RT): https://pubmed.ncbi.nlm.nih.gov/?term=76365303. Albai…

Lots of practice changing new information came out of last week's ESMO conference.This Pod is packed with updates on NSCLC, bladder cancer, gastric cancer, medullary thyroid cancer, KRAS G12C colorectal cancer.....and even bendamustine (non-ESMO update).Από τον John Bossaer

This week we discuss the continued push to introduce 2nd generation androgen inhibitors earlier into treatment with the EMBARK trial.Nivolumab and pembrolizumab, pemrolizumab and nivolumab. Again and again. Their role (and approvals) for adjuvant melanoma make sense. But what to think about their use for NSCLC in the neoadjuvant setting?West commen…

Encorafenib + binimetinib gets FDA-approval for metastatic NSCLC, but how does it compare to dabrafenib/trametinib? Plus, a new pediatric approval for dabrafenib/trametinib means more dosage form options.Από τον John Bossaer

Trying to make sense of the limited information put out via Press Release the last 2 weeks for mobocertinib, pembrolizumab + enfortumab vedotin, nivolumab, and more.Από τον John Bossaer

From the Foundations of OncoPharm archives - the history and groundbreaking STI 571 (imatinib).Από τον John Bossaer

It's another Landmarks of OncoPharm episode looking at the carboplatin-paclitaxel regimen in ovarian cancer from 20 years ago.carboplatin/paclitaxel vs. cisplatin/paclitaxel: https://pubmed.ncbi.nlm.nih.gov/?term=37643542Από τον John Bossaer

An experimental drug for EGFRm NSCLC, patritumab deruxtecan (HER3-DXd), raises some eyebrows and a new agent is FDA-approved for hematopoietic stem cell mobilization (motixafortide).Από τον John Bossaer

You read it in every solid tumor paper - RECIST - criteria. This Pod discusses some of the details of the Response Evaluation in Solid Tumors (RECIST) criteria along with the pros and cons of its use - including a modification of the criteria for use with immunotherapy.Από τον John Bossaer

Empiric dose reductions for variant DPYD alleles isn't necessarily new, but the outcomes of patients treated with those dose reductions isn't well described. Dutch researchers provide some much needed evidence.Link: https://pubmed.ncbi.nlm.nih.gov/?term=37639651Is there a role for ICIs in dMMR/MSI-h pancreatic cancer? This retrospective says, uh ma…

A Foundations of OncoPharm episode on nab-paclitaxel, with a focus on the pharmaceutical differences from conventional paclitaxel.Από τον John Bossaer

A combination product is now available of niraparib + abiraterone for use in mCRPC. Another BCMA-CD3 agent is approved for r/r multiple myeloma and melphalan hepatic arterial infusion for metastatic uveal melanoma is approved.Από τον John Bossaer

Talquetamab is approved for r/r multiple myeloma and the STOP-CA trials asks if atorvastatin can prevent anthracycline cardiotoxicity.STOP-CA: https://jamanetwork.com/journals/jama/fullarticle/2807988Από τον John Bossaer

The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients.Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.Από τον John Bossaer

By listener request! What is BCOP, why pursue it, and some simple tips on studying for the exam.Από τον John Bossaer

A Landmark of OncoPharm from 2004: FOLFIRI --> FOLFOX or FOLFOX --> FOLFIRI.Some interesting dosing to discuss in this study.Link: https://pubmed.ncbi.nlm.nih.gov/?term=37379692Από τον John Bossaer

We welcome Dr. Donald Harvey to the podcast to discuss Phase 1 clinical trials in oncology. Topics include goals of Phase 1 trials, how these early studies are conducted, how doses are determined, and some limitations of current practices.Από τον John Bossaer

We welcome Jacqueline (Jackie) Saunders to the podcast to talk about investigational drug services (IDS) in oncology and how pharmacists manage the storage, preparation, & delivery of experimental drugs.Από τον John Bossaer

This episode...More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II.Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.)NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530FDA…